Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | GRIA1 | P42261 | 4/20 | 0.60 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.60 |
| ▸ | GRIA4 | P48058 | 4/20 | 0.60 |
| ▸ | GRIK5 | Q16478 | 4/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | TYMP | P19971 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TK1 | P04183 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | PYGM | P11217 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20088133 | 0.83 | CYP1A2 (0.57) | KMT2AGRIA1GRIA2GRIA4GRIK5 | |
| SCHEMBL7718378 | 0.81 | KMT2A (0.52) | KMT2AGRIA1GRIA2GRIA4GRIK5 | |
| SCHEMBL31282172 | 0.79 | KMT2A (0.49) | KMT2AGRIA1GRIA2GRIA4GRIK5 | |
| SCHEMBL30423828 | 0.79 | GRIA1 (0.60) | KMT2AGRIA1GRIA2GRIA4GRIK5 | |
| SCHEMBL692624 | 0.79 | LMNA (0.61) | KMT2AGRIA1GRIA2GRIA4GRIK5 | |
| SCHEMBL456749 | 0.79 | HPGD (0.57) | TYMPTK1 | |
| SCHEMBL2153060 | 0.79 | GRIA1 (0.60) | KMT2AGRIA1GRIA2GRIA4GRIK5 | |
| SCHEMBL17123686 | 0.78 | KMT2A (0.49) | KMT2AGRIA1GRIA2GRIA4GRIK5 | |
| SCHEMBL31281981 | 0.77 | KMT2A (0.44) | KMT2AGRIA1GRIA2GRIA4GRIK5 | |
| SCHEMBL136440 | 0.76 | HDAC6 (0.43) | KMT2AGRIA1GRIA2GRIA4GRIK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4182736-A1 | OPTICALLY ACTIVE DEVICES | AMO Ireland (IE) | 2023-05-24 | — | — | EP | disclosed |
| US-20190317040-A1 | DEVICES AND METHODS FOR TARGET MOLECULE CHARACTERIZATION | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-10-17 | — | — | US | disclosed |
| US-10442771-B2 | Trans-base tunnel reader for sequencing | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-10-15 | — | — | US | disclosed |
| US-10330632-B2 | Devices and methods for target molecule characterization | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-06-25 | — | — | US | disclosed |
| US-20170204066-A1 | NANOPORE BASED SEQUENCER | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2017-07-20 | — | — | US | disclosed |
| US-9593372-B2 | Nanopore based sequencer | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2017-03-14 | — | — | US | disclosed |
| US-20160319334-A1 | DETECTION OF NUCLEIC ACID SEQUENCE DIFFERENCES USING THE LIGASE DETECTION REACTION WITH ADDRESSABLE ARRAYS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-11-03 | — | — | US | disclosed |
| US-9395352-B2 | Devices and methods for target molecule characterization | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2016-07-19 | — | — | US | disclosed |
| US-9234241-B2 | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays | CORNELL RESEARCH FOUNDATION, INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-9206477-B2 | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays | CORNELL RESEARCH FOUNDATION, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20100084276-A1 | Devices and Methods for Target Molecule Characterization | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-08 | — | — | US | disclosed |
| WO-2009117517-A2 | NANOPORE AND CARBON NANOTUBE BASED DNA SEQUENCER | ARIZONA BOARD OF REGENTS ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2009-09-24 | — | — | WO | disclosed |
| US-7384749-B2 | Electrodes linked via conductive oligomers to nucleic acids | CLINICAL MICRO SENSORS, INC. (US) | 2008-06-10 | — | — | US | disclosed |
| US-20060211016-A1 | Electrodes linked via conductive oligomers to nucleic acids | CLINICAL MICRO SENSORS, INC. | 2006-09-21 | — | — | US | disclosed |
| US-7056669-B2 | AC methods for the detection of nucleic acids | CLINICAL MICRO SENSORS, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| US-7045285-B1 | Electronic transfer moieties attached to peptide nucleic acids | CLINICAL MICRO SENSORS, INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20030148328-A1 | AC methods for the detection of nucleic acids | ROCHE MOLECULAR SYSTEMS, INC. | 2003-08-07 | — | — | US | disclosed |
| US-6495323-B1 | NUCLEIC ACIDS COVALENTLY COUPLED TO ELECTRODES VIA CONDUCTIVE OLIGOMERS | CLINICAL MICRO SENSORS, INC. | 2002-12-17 | — | — | US | disclosed |
| US-6232062-B1 | HYBRIDIZATION | CLINICAL MICRO SENSORS, INC. | 2001-05-15 | — | — | US | disclosed |
| US-6090933-A | ATTACHING THE SULFUR OF A CONDUCTIVE OLIGOMER HAVING A FIRST SUBUNIT OF A SULFUR ATOM PROTECTED BY ETHYL PYRIDINE OR TRIMETHYLSILYL ETHYL, TO THE GOLD ELECTRODE; NUCLEIC ACIDS COVALENTLY COUPLED TO ELECTRODES VIA CONDUCTIVE OLIGOMERS | CLINICAL MICRO SENSORS, INC. (US) | 2000-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204066-A1 | NANOPORE BASED SEQUENCER | DNMT3A, DNTT, TELO2 | KMT2A 2083/4885GRIA1 4598/4885GRIA2 4167/4885 |
| US-10442771-B2 | Trans-base tunnel reader for sequencing | DNTT, TRDMT1, TELO2 | KMT2A 2184/4885GRIA1 4069/4885GRIA2 3743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.